Renaissance Technologies
SCNI

Renaissance Technologies’s Scinai Immunotherapeutics SCNI Stock Holding History

Renaissance Technologies’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18
Closed -$13K – 4370
2022
Q3 		$13K Hold
18
– – ﹤0.01% 3936
2022
Q2 		$21K Buy
+18
New +$24.7K ﹤0.01% 4113
2021
Q3 		– Sell
-90
Closed -$259K – 3797
2021
Q2 		$259K Buy
+90
New +$280K ﹤0.01% 3189
2020
Q3 		– Sell
-54
Closed -$1.22M – 3646
2020
Q2 		$1.22M Buy
54
+33
+157% +$531K ﹤0.01% 2449
2020
Q1 		$163K Buy
21
+7
+50% +$62K ﹤0.01% 3138
2019
Q4 		$133K Buy
+14
New +$86K ﹤0.01% 3264
2018
Q2 		– Sell
-10
Closed -$55K – 3493
2018
Q1 		$55K Sell
10
-27
-73% -$168K ﹤0.01% 3296
2017
Q4 		$200K Buy
37
+10
+37% +$62.9K ﹤0.01% 3135
2017
Q3 		$192K Buy
+27
New +$222K ﹤0.01% 3009

Other funds holding SCNI

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Renaissance Technologies's SCNI Position: Q4 2022 in Review

Renaissance Technologies sold out of Scinai Immunotherapeutics (SCNI) in Q4 2022, closing a stake of 18 shares — an estimated $13K sold.

Renaissance Technologies first reported a position in SCNI in Q3 2017 and held it in 9 quarters. The position peaked at $1.22M in Q2 2020. 8 funds tracked by Wall St. Rank hold SCNI as of Q4 2022.

  • Renaissance Technologies reported no remaining Scinai Immunotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Renaissance Technologies sold 18 Scinai Immunotherapeutics shares in Q4 2022, an estimated $13K.
  • Renaissance Technologies first reported a position in Scinai Immunotherapeutics in Q3 2017 and held it in 9 quarters.
  • Renaissance Technologies's Scinai Immunotherapeutics position peaked at $1.22M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.